Left Atrial Low vOltage Zone, GenetIC Markers and Outcomes in Patients After Atrial Fibrillation abLation
NCT ID: NCT02074826
Last Updated: 2015-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2014-03-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Left atrial fibrosis is increasingly recognized as a fundamental part of the pathomorphological substrate creating an electrophysiological environment needed for electrical conduction heterogeneities. Such identification and treatment of left atrial fibrosis has already entered routine clinical use for RF catheter ablation in an attempt to develop an individualized and tailored treatment strategy. Today, it is unclear what impacts the development, the extent and the localization of left atrial fibrosis in different patients.
A number of genetic risk variants have been described that confer risk of AF and have been widely replicated. This indicates that genetic variants contribute to the risk of the individual to develop AF throughout his life. However, the mechanisms of how genetic variant impact the development of clinical arrhythmias is not yet well understood.
We hypothesize that genetic influences that lead to tissue changes may play a role in the development of the arrhythmia substrate for AF. This is likely to be especially true for those with a relatively brief history of AF and modest clinical disease burden. Therefore, we plan to investigate the association between known genetic AF variants and a detailed disease phenotype obtained from individual left atrial voltage mapping.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association of Genetic Polymorphisms With Atrial Fibrosis and Thrombogenic Substrate in Patients With Non-valvular Atrial Fibrillation
NCT03560219
The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation.
NCT04753541
Atrial Fibrillation Ablation Registry
NCT03075930
Investigation of Genetic Risk of Atrial Fibrillation
NCT00412438
Risk Profile for Patients With Atrial Fibrillation
NCT01510210
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For genetic testing blood samples in EDTA (ethylenediaminetetraacetic) vacutainers will be collected from the study participants that will be performed at deCODE genetics in Reykjavik, Iceland. Samples will be frozen at -20°C and shipped to deCODE (deCODE genetics, Sturlugata 8, IS-101 Reykjavik, Iceland) in batches on ice. All sample handling, DNA isolation, and genotyping at deCODE will be performed in Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) accredited laboratories. The blood samples collected will be labelled using stickers with encrypted identifiers provided by deCODE. The key linking encrypted identifiers and the patient names will be stored in a secure location by the primary investigator in Dresden, Germany. The clinical data sent to deCODE will be encrypted in the same manner. Neither participants or third parties (e.g. health care insurance companies) will have any access to the genetic information collected.
Genotyping of the AF associated variants: DNA will be isolated in deCODE's CLIA and CAP accredited diagnostics laboratory from blood samples using the Chemagen method (Perkin Elmer). The SNPs (single nucleotide polymorphism) outlined in Table 1 will be genotyped using the Centaurus (Epoch Biosciences) platform. The genotyping of these markers have been analytically validated at deCODE using a comprehensive validated LIMS (Laboratory Information Management System) system that tracks every step in the process from registration to the final test report. Genotyping results for study participants will be stored in deCODE database under encrypted identifiers.
Prior to the ablation procedure, transesophageal echocardiography will be performed to exclude thrombus formation within the LA (left atrium). Electrophysiological studies are going to be performed in the post-absorptive state under deep sedation using midazolam and propofol. All antiarrhythmic medications will be discontinued at least five half-lives before the study, except amiodarone. Conventional 12-lead surface ECG (filtered 0.05-100 Hz) and bipolar intracardiac electrogram recordings (filtered 30-500 Hz) are amplified and displayed on Bard Laboratory System, (Bard Electrophysiology, Billerica, MA). A quadripolar and a decapolar catheter are introduced via the left femoral vein into the right ventricular apex and coronary sinus (CS) with a proximal pole at the CS ostium respectively. If atrial fibrillation (AF) is present in the beginning, a electric cardioversion (up to 3 times) will be performed to obtain sinus rhythm (SR).
A single transseptal puncture under fluoroscopic guidance will provide access into the LA. Repeated doses of heparin will be used to maintain an activated clotting time of 250 to 350 seconds throughout the whole procedure.
Mapping and ablation procedures will be guided by a 3D electroanatomical mapping system (CARTO 3, Biosense Webster, Inc., Diamond Bar, CA, USA or Ensite-Velocity, Endocardial Solutions, Inc., St. Paul, Minnesota, USA) in all patients. To quantify the amount of left atrial fibrosis, a bipolar voltage map will be carried out simultaneously during the CT-based 3D reconstruction of left atrium. All points will be taken in sinus rhythm. Radiofrequency alternating current will be delivered in a unipolar mode between the irrigated-tip electrode of the ablation catheter (Surround Flow, Biosense Webster or IBI Therapy CoolFlex, St. Jude Medical) and an external back plate electrode. The standard ablation settings include a preselected power of 40 W, and a flow rate of 15 or 17 ml/min (15 ml/min for Surround Flow, and 17 ml/min for CoolFlex). A temperature probe in the esophagus at the level of the LA is used to tag the esophageal location and to provide intraesophageal temperature feedback during the procedure. For the ablation procedure a ablation protocol is completed.
The following procedure data is recorded:
* Procedure date
* Initial rhythm: sinus rhythm, atrial fibrillation, atrial tachycardia
* Procedure time
* Fluoroscopy time and dose
* Ablation duration
* Ablation energy
* Isolation of each pulmonary vein
* Adverse events / procedure-related events: tamponade, stroke, myocardial infarction, pulmonary embolism, pulmonary edema
The primary end point is reached when a detailed endocardial voltage mapping has been performed and correlated with the suggested genetic AF markers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atrial fibrillation
* Genotyping of the AF associated variants
* Measurement of the amount of left atrial fibrosis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Paroxysmal or persistent symptomatic atrial fibrillation
* Ineffectiveness of antiarrhythmic medication (at least 1 medication) or indication for primary AF ablation according to current guidelines
* Age 18-75 years
Exclusion Criteria
* Pregnancy
* Women of childbearing potential without a negative pregnancy test within 48 hours prior to the ablation procedure
* Known intracardiac or other thrombi
* Contraindication to anticoagulation
* Previous left atrial ablation
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Landspitali University Hospital
OTHER
Technische Universität Dresden
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mathias Forkmann
Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher Piorkowski, PD
Role: STUDY_CHAIR
Department of Electrophysiology, University of Dresden - Heart Center
David O. Arnar, Dr
Role: STUDY_CHAIR
Department of Cardiology, Landspitali University Hospital Heart
Thomas P Gaspar, Dr.
Role: PRINCIPAL_INVESTIGATOR
Department of Electrophysiology, University of Dresden - Heart Center
Mathias Forkmann, Dr.
Role: PRINCIPAL_INVESTIGATOR
Department of Electrophysiology, University of Dresden - Heart Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Heart Center Dresden, Depart. of Electrophysiology
Dresden, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GEN-AFIB-REG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.